{"Among": [0, 341], "patients": [1, 48, 342], "with": [2, 49, 53, 86, 343, 370], "resectable": [3, 54], "early-stage": [4, 50, 345], "non\u2013small-cell": [5], "lung": [6], "cancer": [7], "(NSCLC),": [8], "a": [9, 29, 37, 66, 280], "perioperative": [10, 45], "approach": [11, 26], "that": [12, 130], "includes": [13], "both": [14], "neoadjuvant": [15, 71, 347, 371], "and": [16, 95, 142, 155, 168, 197, 230, 258, 279, 287, 314, 333, 354, 364, 393], "adjuvant": [17, 96, 355], "immune": [18], "checkpoint": [19], "inhibition": [20], "may": [21], "provide": [22], "benefit": [23], "beyond": [24], "either": [25], "alone.": [27], "Download": [28], "PDF": [30], "of": [31, 82, 127, 159, 251, 261, 307, 316, 326], "the": [32, 124, 132, 165, 171, 175, 180, 194, 200, 227, 233, 241, 252, 255, 264, 308, 311, 319, 384], "Research": [33], "Summary.": [34], "We": [35], "conducted": [36], "randomized,": [38], "double-blind,": [39], "phase": [40], "3": [41, 79, 104, 328], "trial": [42], "to": [43, 69, 108, 123, 164, 170, 216, 274, 297], "evaluate": [44], "pembrolizumab": [46, 72, 97, 166, 195, 228, 256, 312, 348, 356], "in": [47, 65, 193, 199, 226, 232, 249, 254, 259, 263, 285, 310, 318, 386], "NSCLC.": [51], "Participants": [52], "stage": [55], "II,": [56], "IIIA,": [57], "or": [58, 75, 100, 138, 140, 208, 329], "IIIB": [59], "(N2": [60], "stage)": [61], "NSCLC": [62], "were": [63, 116, 162], "assigned": [64, 163], "1:1": [67], "ratio": [68, 204], "receive": [70], "(200": [73, 98], "mg)": [74, 99], "placebo": [76, 101, 172, 201, 234, 265, 320], "once": [77, 102], "every": [78, 103], "weeks,": [80], "each": [81], "which": [83, 237], "was": [84, 183, 191, 224], "given": [85], "cisplatin-based": [87], "chemotherapy": [88, 350, 372], "for": [89, 106, 205, 404], "4": [90], "cycles,": [91], "followed": [92, 351, 374], "by": [93, 352, 375, 390], "surgery": [94], "weeks": [105], "up": [107], "13": [109], "cycles.": [110], "The": [111, 219], "dual": [112], "primary": [113], "end": [114, 146], "points": [115, 147], "event-free": [117, 359], "survival": [118, 187, 223, 378], "(the": [119], "time": [120], "from": [121], "randomization": [122], "first": [125, 177], "occurrence": [126], "local": [128], "progression": [129, 137], "precluded": [131], "planned": [133], "surgery,": [134], "unresectable": [135], "tumor,": [136], "recurrence,": [139, 207], "death)": [141], "overall": [143, 222], "survival.": [144], "Secondary": [145], "included": [148], "major": [149, 245, 361], "pathological": [150, 152, 246, 281, 362, 365], "response,": [151, 154, 363], "complete": [153, 282, 366], "safety.": [156], "A": [157, 244], "total": [158], "397": [160], "participants": [161, 253, 309], "group,": [167], "400": [169], "group.": [173], "At": [174], "prespecified": [176], "interim": [178], "analysis,": [179], "median": [181], "follow-up": [182], "25.2": [184], "months.": [185], "Event-free": [186], "at": [188], "24": [189], "months": [190], "62.4%": [192], "group": [196, 202, 229, 235, 257, 266, 313, 321], "40.6%": [198], "(hazard": [203], "progression,": [206], "death,": [209], "0.58;": [210], "95%": [211, 271, 294], "confidence": [212], "interval": [213], "[CI],": [214], "0.46": [215], "0.72;": [217], "P<0.001).": [218], "estimated": [220], "24-month": [221], "80.9%": [225], "77.6%": [231], "(P=0.02,": [236], "did": [238, 379], "not": [239, 380], "meet": [240], "significance": [242], "criterion).": [243], "response": [247, 283, 367], "occurred": [248, 284], "30.2%": [250], "11.0%": [260], "those": [262, 317], "(difference,": [267, 290], "19.2": [268], "percentage": [269, 292], "points;": [270, 293], "CI,": [272, 295], "13.9": [273], "24.7;": [275], "P<0.0001;": [276, 299], "threshold,": [277, 300], "P=0.0001),": [278], "18.1%": [286], "4.0%,": [288], "respectively": [289], "14.2": [291], "10.1": [296], "18.7;": [298], "P=0.0001).": [301], "Across": [302], "all": [303], "treatment": [304], "phases,": [305], "44.9%": [306], "37.3%": [315], "had": [322, 337], "treatment-related": [323], "adverse": [324], "events": [325], "grade": [327, 338], "higher,": [330], "including": [331], "1.0%": [332], "0.8%,": [334], "respectively,": [335], "who": [336], "5": [339], "events.": [340], "resectable,": [344], "NSCLC,": [346], "plus": [349], "resection": [353], "significantly": [357, 382], "improved": [358], "survival,": [360], "as": [368], "compared": [369], "alone": [373], "surgery.": [376], "Overall": [377], "differ": [381], "between": [383], "groups": [385], "this": [387], "analysis.": [388], "(Funded": [389], "Merck": [391], "Sharp": [392], "Dohme;": [394], "KEYNOTE-671": [395], "ClinicalTrials.gov": [396], "number,": [397], "NCT03425643.)": [398], "QUICK": [399], "TAKE": [400], "VIDEO": [401], "SUMMARYNeoadjuvant": [402], "Pembrolizumab": [403], "Lung": [405], "Cancer": [406], "02:12": [407]}